Roberta Guagliardo

Ms. Roberta Guagliardo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
RGRoberta Guagliardo
Roberta Guagliardo
Jesus Perez GilJesus Perez Gil
Jesus Perez Gil
SSStefaan De Smedt
Stefaan De Smedt
KRKoen Raemdonck
Koen Raemdonck

1 September 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
PMPieterjan Merckx
Pieterjan Merckx
LBLynn De Backer
Lynn De Backer
LHLien Van Hoecke
Lien Van Hoecke
RGRoberta Guagliardo
Roberta Guagliardo
MEMercedes Echaide
Mercedes Echaide
KRKoen Raemdonck
Koen Raemdonck

24 August 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
BBBram Bogaert
Bram Bogaert
FSFélix Sauvage
Félix Sauvage
RGRoberta Guagliardo
Roberta Guagliardo
CMCristina Muntean
Cristina Muntean
VNVan Phuc Nguyen
Van Phuc Nguyen
KRKoen Raemdonck
Koen Raemdonck

16 March 2021 in ACS Nano
Verified
Journal Article
Closed access
RGRoberta Guagliardo
Roberta Guagliardo
LHLore Herman
Lore Herman
JPJelle Penders
Jelle Penders
AZAgata Zamborlin
Agata Zamborlin
HKHerlinde De Keersmaecker
Herlinde De Keersmaecker
KRKoen Raemdonck
Koen Raemdonck

1 December 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
PMPieterjan Merckx
Pieterjan Merckx
JLJoris Lammens
Joris Lammens
GNGust Nuytten
Gust Nuytten
BBBram Bogaert
Bram Bogaert
RGRoberta Guagliardo
Roberta Guagliardo
KRKoen Raemdonck
Koen Raemdonck

23 August 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RGRoberta Guagliardo
Roberta Guagliardo
PMPieterjan Merckx
Pieterjan Merckx
AZAgata Zamborlin
Agata Zamborlin
LBLynn De Backer
Lynn De Backer
MEMercedes Echaide
Mercedes Echaide
KRKoen Raemdonck
Koen Raemdonck
Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its encapsulation in a suitable (nanosized) delivery system. On the intracellular level, the endosomal membrane is a major barrier following endocytosis of siRNA-loaded nanoparticles in target cells and innovative materials to promote cytosolic siRNA delivery are highly sought after. We previously identified the endogenous lung surfactant protein B (SP-B) as siRNA delivery enhancer when reconstituted in (proteo) lipid-coated nanogels. It is known that the surface-active function of SP-B in the lung is influenced by the lipid composition of the lung surfactant. Here, we investigated the role of the lipid component on the siRNA delivery-promoting activity of SP-B proteolipid-coated nanogels in more detail. Our results clearly indicate that SP-B prefers fluid membranes with cholesterol not exceeding physiological levels. In addition, SP-B retains its activity in the presence of different classes of anionic lipids. In contrast, comparable fractions of SP-B did not promote the siRNA delivery potential of DOTAP:DOPE cationic liposomes. Finally, we demonstrate that the beneficial effect of lung surfactant on siRNA delivery is not limited to lung-related cell types, providing broader therapeutic opportunities in other tissues as well.